Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor (DXR) reported significant growth in its fiscal year 2024, with its NAV increasing to $7.25 per share from $7.08 in 2023. The company's operating division achieved remarkable results, including a 116.5% revenue increase year-over-year.
Key highlights include:
- 60.1% growth in diagnostic kit sales
- 12 new customer accounts in 2024
- Achievement of cash-flow break-even in Q1 2025 (excluding non-cash expenses)
- Secured $2.5M DoD contract
- Received over $350K in NIH and Launch Tennessee grants
The company is preparing to file for FDA approval of its next-generation blood volume analyzer through the 510(k) pathway. This point-of-care system aims to enhance clinical workflows in critical care settings and expand market opportunities in both hospital and outpatient environments.
Daxor (DXR) has expanded its blood volume analysis (BVA) services to a major 735-bed Midwest healthcare facility. The healthcare center will implement Daxor's ezBVA Lab service for outpatient cardiovascular care, focusing on patients with heart failure and hypertension.
Blood samples will be processed at Daxor's CLIA-certified Tennessee facility, providing comprehensive BVA results within 24 hours. The BVA diagnostic offers 98% accuracy in fluid management data, helping clinicians optimize patient care. The service is fully reimbursable through CPT codes for both inpatient and outpatient settings under public and private insurance plans.
Daxor (Nasdaq: DXR) has expanded its blood volume analysis (BVA) technology to two major hospitals within New Jersey's largest academic health care system. The hospitals are implementing on-site BVA analyzers to enable immediate access to precise blood volume measurements for critical care decisions.
The implementation aims to optimize fluid management, reduce hospital stays, and improve outcomes for heart failure and critical care patients. According to CEO Michael Feldschuh, the expansion demonstrates the effectiveness of their growth strategy, with dedicated resources in sales and marketing delivering meaningful results. The company expects to maintain this accelerated sales trajectory throughout 2025.
Daxor (DXR) announced new research findings from Duke University Medical Center and Yale School of Medicine presented at the Technology and Heart Failure Therapeutics Conference (THT) in February 2025. The studies focus on the company's Blood Volume Analysis (BVA) technology.
The Duke study revealed no correlation between pulmonary artery pressure readings and actual blood volume measured by BVA, challenging industry assumptions about pressure monitoring as a proxy for volume measurement in heart failure care.
The Yale study, conducted over 5 years, examined diuretic mechanism of action using BVA, demonstrating the technology's accuracy in detecting volume shifts. The research provided new insights into the fluid removal process and highlighted BVA's potential to improve treatment for millions of patients on diuretic therapy.
TruLite Health, developer of health equity solutions, has expanded its leadership team with key appointments. Walter D. Conwell, MD, MBA, former chief diversity officer at Morehouse School of Medicine, has been appointed as president. The company also added two board members: Edmondo Robinson, MD, MBA, a digital health leader and Ardent Health Services board member, and Caleb DesRosiers, JD, MPA, a pharmaceutical executive.
TruLite's main product, Truity™, is software that integrates with electronic health records to address clinical bias at the point of care. The solution uses explainable AI and machine learning to drive patient-specific clinical, social, and behavioral interventions, aiming to improve healthcare outcomes and costs. The software aligns with regulatory requirements from the Joint Commission, CMS, and FDA.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, will exhibit at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress in Orlando, FL from February 23-25, 2025, at Booth #532.
The company's Blood Volume Analysis (BVA) technology has demonstrated significant impact in ICU settings, where there are 5.7 million annual admissions costing $108 billion in the United States. Peer-reviewed studies show BVA technology alters fluid and red blood cell interventions in 44% of cases and reduces mortality by 66% in surgical intensive care units, while also decreasing hospital stays and ventilator days.
Daxor (Nasdaq: DXR) announces a breakthrough study published in JACC: Case Reports revealing a distinct heart failure phenotype through their blood volume analysis (BVA) technology. The research, examining 179 advanced heart failure patients, identified that 20% (36 patients) exhibited a specific hypervolemia/polycythemia phenotype characterized by expanded blood volume overload and elevated red blood cells.
The condition potentially affects 700,000-1,400,000 US heart failure patients, representing 10-20% of ambulatory cases. Four patients received therapeutic phlebotomy treatment guided by BVA, resulting in significant symptom improvement with zero hospitalizations or deaths over a 12-month monitoring period. The study highlights that patients with this phenotype typically show worse clinical outcomes and face higher stroke and blood clot risks if untreated.
Daxor (Nasdaq: DXR) announces a multicenter study published in the Journal of Cardiac Failure demonstrating the superiority of their Blood Volume Analysis (BVA) technology in heart failure treatment. The study, involving 255 heart failure patients across Mayo Clinic, Duke University Medical Center, and Baptist Hospital in Memphis, revealed that BVA outperforms standard hemodynamic measurements in assessing heart failure volume status.
The research, titled 'Patient Sex Impacts Volume Phenotypes and Hemodynamics in Chronic Heart Failure,' highlighted three key findings: hemodynamic pressure measures are less accurate compared to BVA, the technology enables more precise anemia diagnosis, and sex-specific volume differences require individualized treatment approaches. The study confirms BVA's 98% accuracy in volume measurement, establishing it as a important tool for precise heart failure diagnosis and treatment.
Daxor (DXR) announces expansion of its ezBVA Lab blood volume analysis service to two new health systems. The expansion includes an Arizona-based multi-campus medical center for outpatient nephrology care and a regional health network serving Southwest Iowa, Nebraska, Minnesota, and North Dakota for heart failure outpatient management.
The ezBVA Lab service provides cost-effective blood volume analysis with minimal initial investment and broad reimbursement coverage. The company reports this expansion contributes to their strongest quarter ever in terms of revenue and year-over-year growth.
Daxor (NASDAQ: DXR), the global leader in blood volume measurement technology, will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference from October 17-19, 2024, in Aurora, CO. This elite conference unites cardiovascular thought-leaders to transform care and introduce innovative solutions.
Daxor's CEO, Michael Feldschuh, emphasized the opportunity to showcase their BVA-100™ Blood Volume Diagnostic, which addresses key challenges in cardiovascular care. Peer-reviewed studies have shown that BVA-guided care significantly improves patient outcomes, including:
- 82% reduction in 30-day mortality
- 86% reduction in 1-year mortality
- 56% reduction in 30-day readmissions
- 57% reduction in length of stay when performed upon admission
The BVA technology provides 98% accurate, actionable data for optimizing treatment plans and individualizing care, ultimately improving outcomes while reducing duration and cost.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
